You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePotassium Iodide
Accession NumberDB06715
Typesmall molecule
Groupsapproved
Description

Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperglycemia (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.

Structure
Thumb
Synonyms
SynonymLanguageCode
KaliumiodidNot AvailableNot Available
KINot AvailableNot Available
Potassium iodideNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
ThyroShieldNot Available
Brand mixturesNot Available
CategoriesNot Available
CAS number7681-11-0
WeightAverage: 166.0028
Monoisotopic: 165.868175281
Chemical FormulaIK
InChI KeyNLKNQRATVPKPDG-UHFFFAOYSA-M
InChI
InChI=1S/HI.K/h1H;/q;+1/p-1
IUPAC Name
potassium iodide
SMILES
[K+].[I-]
Mass SpecNot Available
Taxonomy
KingdomInorganic Compounds
SuperclassMixed Metal/Non-metal Compounds
ClassAlkali Metal Salts
SubclassAlkali Metal Iodides
Direct parentAlkali Metal Iodides
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionThis compound belongs to the alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
Pharmacology
IndicationPotassium Iodide is oral antithyroid agent. Potassium Iodide is used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution.
PharmacodynamicsIt works in the thyroid gland. By inhibiting thyroid hormone synthesis and release, thyroid gland vascularity is reduced, thyroid gland tissue becomes firmer, thyroid cell size is reduced, follicular colloid reaccumulates, and bound iodine levels increase. As a protectant following radiation exposure, KI blocks the uptake of radioactive iodine isotopes by the thyroid gland thereby minimizing the risk of radiation-induced thyroid neoplasms.
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.7647
Blood Brain Barrier + 0.9702
Caco-2 permeable + 0.6625
P-glycoprotein substrate Non-substrate 0.8989
P-glycoprotein inhibitor I Non-inhibitor 0.984
P-glycoprotein inhibitor II Non-inhibitor 0.9854
Renal organic cation transporter Non-inhibitor 0.9282
CYP450 2C9 substrate Non-substrate 0.8261
CYP450 2D6 substrate Non-substrate 0.7789
CYP450 3A4 substrate Non-substrate 0.7857
CYP450 1A2 substrate Non-inhibitor 0.7164
CYP450 2C9 substrate Non-inhibitor 0.8527
CYP450 2D6 substrate Non-inhibitor 0.9142
CYP450 2C19 substrate Non-inhibitor 0.8842
CYP450 3A4 substrate Non-inhibitor 0.9317
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9022
Ames test Non AMES toxic 0.6838
Carcinogenicity Carcinogens 0.659
Biodegradation Not ready biodegradable 0.5913
Rat acute toxicity 2.9202 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9535
hERG inhibition (predictor II) Non-inhibitor 0.9657
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Fleming and co pharmaceuticals
  • Anbex inc
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Recip ab
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
Statesolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
physiological charge1ChemAxon
hydrogen acceptor count0ChemAxon
hydrogen donor count0ChemAxon
polar surface area0ChemAxon
rotatable bond count0ChemAxon
refractivity0ChemAxon
polarizability1.78ChemAxon
number of rings0ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleYesChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Stanley D. Lazarus, “Production of thermally stabilized polyester with alkylene carbonates and sodium or potassium iodide.” U.S. Patent US4327207, issued October, 1973.

US4327207
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD01016
KEGG CompoundC08219
PubChem Compound4875
PubChem Substance99443267
ChemSpider4709
WikipediaSSKI
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Tyrosine

Kind: small molecule

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details

References:

  1. Pisarev MA, Aiello LO: Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis. Acta Endocrinol (Copenh). 1976 Jun;82(2):298-305. Pubmed
  2. Foldes J, Gesztesi E, Juhasz J: Mechanism of action of di-iodotyrosine and of iodine. Acta Med Acad Sci Hung. 1974;31(1-2):131-7. Pubmed

Comments
comments powered by Disqus
Drug created on May 16, 2010 17:39 / Updated on September 16, 2013 18:04